Editor’s picks: exploring in vivo cell and gene therapies

In vivo cell and gene therapies are entering a defining phase of development. From single-dose genome editing treatments to emerging approaches that engineer immune cells directly in the body, the field is rapidly expanding beyond its original technical boundaries. At the same time, significant scientific and translational questions remain. Delivery precision, safety evaluation, manufacturing scalability, and clinical trial design continue to shape how quickly these therapies can move from experimental promise to routine clinical use. To explore these challenges and opportunities, we have curated a selection of interviews with scientists and industry leaders working at the forefront of in vivo innovation. Together, they offer differing perspectives on the technologies, clinical strategies, and global ecosystems shaping the next generation of cell and gene therapies.